ShangPharma opens pilot plant in Shanghai

Published: 17-Jan-2011
Design & Build Manufacturing Regulatory Research & Development Cleaning Analysis Pharmaceutical

For pharma development and cGMP manufacturing

ShangPharma Corporation, a China-based contract research and manufacturing organisation, has started operations at a new manufacturing facility in the Shanghai suburb of Fengxian.

The new multi-purpose pharmaceutical development and cGMP manufacturing facility will allow ShangPharma to support its clients Phase II and Phase III trials, expanding its service offering to include process and formulation r&d, analytical method development and validation, and cGMP manufacturing of intermediates and APIs.

Previously the CRO/CMO provided clients with materials for early discovery and GLP toxicology testing and Phase I clinical trials.

ShangPharma said it might further expand its manufacturing facilities if there is demand for commercial manufacturing of FDA- or EMEA-approved drugs.

The Fengxian facility will operate as a wholly owned subsidiary of the company under the name China Gateway Pharmaceutical Development Co. It includes a pilot plant that supports six separate bays with reactor capacities ranging from 200 to 3,000 litres and other speciality bays with reactor capacities ranging from 50 to 2000 litres for high temperature, cryogenics, highly toxic and pressurised reactions, including hydrogenation.

The company said there are also two cleanroom suites rated at Class 100,000 for isolation, 10 kilo-lab suites for bothnon-cGMP and cGMP manufacturing, as well as a large r&d laboratory for analytical, formulation and process development activities.

In addition, there are separate buildings for utilities, materials management, warehouse storage and waste water treatment with room for further expansion to support commercial manufacturing activities.

Testing of raw materials, intermediates and final products will be carried out at the site. An independent quality assurance department will ensure that materials are manufactured in accordance with cGMP requirements and that established standard operating procedures are followed, the firm said.

See more

You may also like

Manufacturing

BIA report highlights UK innovation and efficiency in global cell and gene therapy sector

Read more
The report provides a comprehensive analysis of the UK's cell and gene therapy sector, focusing on the innovative technologies and strategic investments that are driving scale

Trending Articles

  1. Manufacturing Chemist Stand Side with Piramal Pharma Solutions We discover what exhibitors at CPHI 2025 are showcasing LIVE!
  2. Thermo Fisher launches general purpose centrifuges with natural refrigerant cooling New X and S Series models offer high performance with reduced environmental impact
  3. UK-US pharma deal removes tariffs and boosts access to innovative medicines The UK has secured a zero-tariff agreement on pharmaceutical exports to the US, alongside major reforms to accelerate NHS access to new treatments
  4. Rentschler Biopharma and Coriolis Pharma partner to deliver integrated biopharma development and manufacturing solutions The German-based CDMO and CRDO will offer unified formulation-to-manufacturing services to accelerate biologics development. The collaboration aims to cut complexity, timelines and risk for global biopharma clients

Upcoming event

From powder to granules: a deep dive into wet granulation methods

14 January 2026 | Virtual See all

You may also like

Manufacturing

BIA report highlights UK innovation and efficiency in global cell and gene therapy sector

The report provides a comprehensive analysis of the UK's cell and gene therapy sector, focusing on the innovative technologies and strategic investments that are driving scale
Manufacturing

Vacuubrand at a glance - New brochure available to download

In the UK, Labtex supplies a comprehensive range of high-quality laboratory and instrumentation vacuum pumps, gauges and controllers for both coarse and fine vacuums, from trusted partners at Vacuubrand
Regulatory

BIOSECURE Act on track to curb Chinese biotech investment in the US

The amended Act was included in the annual defence bill after failing to pass muster in the last key defence spending bill, but has some notable omissions
Regulatory

One in four European pharma companies at risk of regulatory breaches according to NSF research

The independent survey exposed significant gaps in quality systems, supply chain oversight and data integration, just as EU GMP regulations continue to tighten
Manufacturing

SeaBeLife partners with Unither Pharmaceuticals for ophthalmic drug production

The new partnership aims to produce clinical and commercial batches of ophthalmic formulation of SeaBeLife’s drug candidate SBL03 to treat degenerative disorders of the retina, such as dry age-related macular degeneration
Pharmaceutical

SGS achieves breakthrough in infectious disease research with launch of novel RSV A-strain

Derived from a 2015 circulating strain, SGS's novel RSV-A challenge agent offers a closer match to circulating RSV viruses than strains currently used in clinical research
Research & Development

Poolbeg Pharma trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme

Poolbeg will act as the lead business partner, alongside Johnson & Johnson and other partners, on the University of Manchester and The Christie NHS Foundation Trust research programme titled RISE (Reducing Immune Stress from Excess cytokine release in advanced therapies)
Subscribe now